文献速递肝病消化道肿瘤与早癌

肝病病因变化支持降低甲胎蛋白肝癌筛查阈值

Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.
PubMed 文献 · Gastroenterology · 2025-11-14

基于退伍军人健康管理局(VHA)与器官共享联合网络数据,评估肝硬化患者肝癌筛查中甲胎蛋白(AFP)的表现。随病因向ALD、MASLD及治愈丙肝转变,诊断时AFP中位数下降;将筛查阈值从≥20降至≥10 ng/mL可明显提高敏感性且特异性仍很高。

要点

  • 肝癌诊断时AFP中位数随年份下降,以活动性丙肝最高、MASLD最低
  • 阈值≥20与≥10 ng/mL总体敏感性分别为31.7%与41.9%,特异性98.5%与94.1%
  • 在MASLD、ALD、治愈丙肝肝硬化中降至≥10 ng/mL可大幅提高敏感性

核心结论

  • 对MASLD、ALD和治愈丙肝肝硬化人群,将AFP筛查阈值降至≥10 ng/mL可显著提高敏感性并维持很高特异性。

研究设计与样本

  • 利用VHA与United Network for Organ Sharing数据,评估AFP在肝癌诊断时的趋势并估算其在肝硬化人群中的筛查检测性能。
  • VHA分析纳入2001至2021年诊断肝癌的40,399例患者,以及2019年接受照护的28,170例肝硬化患者(其中1,029例在2019年发生肝癌)。
  • United Network for Organ Sharing分析纳入26,213例肝癌患者。

主要发现

  • 肝癌诊断时AFP中位数随时间下降,活动性丙肝为32.7 ng/mL,治愈丙肝8.3、ALD 9.0、MASLD 7.7 ng/mL。
  • VHA肝硬化队列中活动性丙肝占9.6%、治愈丙肝43%、ALD 24%、MASLD 14%。
  • VHA队列阈值≥20与≥10 ng/mL的总体敏感性/特异性分别为31.7%/98.5%与41.9%/94.1%。

关键数值与推荐

  • VHA队列阈值由≥20降至≥10 ng/mL:活动性丙肝敏感性43.7%升至60.7%、特异性92.6%降至83.0%。
  • 治愈丙肝敏感性32.5%升至41.5%、特异性99.0%降至94.7%;ALD敏感性22.8%升至32.3%、特异性99.2%降至95.1%。
  • MASLD敏感性21.7%升至29.9%、特异性99.4%降至96.7%。
  • United Network for Organ Sharing队列阈值由≥20降至≥10 ng/mL总体敏感性31.8%升至48.7%。
  • 该队列活动性丙肝36.7%升至58.6%、治愈丙肝21.4%升至36.4%、MASLD 19.1%升至33.4%、ALD 15.9%升至27.1%。

临床怎么用

  • 在MASLD、ALD及治愈丙肝相关肝硬化人群开展肝癌筛查时,可考虑采用AFP≥10 ng/mL作为筛查阳性阈值。
  • 阈值下调后需结合各病因特异性下降幅度解读阳性结果,避免过度召回。

局限性

  • AFP检测性能基于VHA与器官移植登记数据估算,外推至其他人群需谨慎。
  • 原文未报告阈值调整对筛查成本、召回率及临床结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Serum alpha-fetoprotein (AFP) is a key component of hepatocellular carcinoma (HCC) screening, but its test characteristics are uncertain as alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD) rates increase. METHODS: We evaluated AFP trends at HCC diagnosis and estimated its test performance for HCC screening in cirrhosis using Veterans Health Administration (VHA) and United Network for Organ Sharing data. RESULTS: Among the 40,399 VHA patients diagnosed with HCC between 2001 and 2021, median AFP at HCC diagnosis declined over time and was highest in active-hepatitis C (HCV) (32.7 vs cured-HCV 8.3, ALD 9.0, MASLD 7.7 ng/mL). Among the 28,170 VHA patients with cirrhosis receiving care in 2019 (9.6% active-HCV, 43% cured-HCV, 24% ALD, 14% MASLD), 1,029 developed HCC in 2019. At AFP thresholds ≥20 and ≥10 ng/mL, the overall sensitivity/specificity for HCC screening was 31.7%/98.5% and 41.9%/94.1%, respectively. Lowering the AFP threshold to ≥10 ng/mL increased sensitivity with minimal reductions in specificity across all liver disease etiologies: active-HCV (sensitivity/specificity: 43.7% to 60.7%/92.6% to 83.0%), cured-HCV (32.5% to 41.5%/99.0% to 94.7%), ALD (22.8% to 32.3%/99.2% to 95.1%), and MASLD (21.7% to 29.9%/99.4% to 96.7%). Analysis of United Network for Organ Sharing (26,213 patients with HCC) resulted in similar increases in test sensitivity as the AFP threshold declined from ≥20 to ≥10 ng/mL (overall: 31.8% to 48.7%; active-HCV: 36.7% to 58.6%, cured-HCV: 21.4% to 36.4%, MASLD: 19.1% to 33.4%, and ALD: 15.9% to 27.1%). CONCLUSIONS: For HCC screening in MASLD, ALD, and cured-HCV cirrhosis, reducing the AFP threshold to ≥10 ng/mL would substantially increase sensitivity while maintaining very high specificity.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kim NJ, Li M, Vutien P, et al. Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening. Gastroenterology. 2025. PMID: 41236449. doi:10.1053/j.gastro.2025.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。